Search

Frank S. Chen

Examiner (ID: 12596, Phone: (571)270-7993 , Office: P/2611 )

Most Active Art Unit
2611
Art Unit(s)
2677, 2611
Total Applications
884
Issued Applications
701
Pending Applications
78
Abandoned Applications
123

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 20622653 [patent_doc_number] => 12590152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => CD3-specific binding molecules [patent_app_type] => utility [patent_app_number] => 17/427592 [patent_app_country] => US [patent_app_date] => 2020-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 7631 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17427592 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/427592
CD3-specific binding molecules Jan 29, 2020 Issued
Array ( [id] => 18212718 [patent_doc_number] => 20230058982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => ANTI-CTLA-4 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/788998 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788998 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/788998
ANTI-CTLA-4 ANTIBODY AND USE THEREOF Dec 26, 2019 Abandoned
Array ( [id] => 17414113 [patent_doc_number] => 20220049017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/299147 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41669 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299147 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/299147
PCSK9 antagonists Dec 17, 2019 Issued
Array ( [id] => 17852174 [patent_doc_number] => 20220282216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => Primary NK CAR Constructs And Methods [patent_app_type] => utility [patent_app_number] => 17/311226 [patent_app_country] => US [patent_app_date] => 2019-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311226 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/311226
Primary NK CAR constructs and methods Nov 25, 2019 Issued
Array ( [id] => 17561754 [patent_doc_number] => 20220125903 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => METHODS FOR IMPROVING THE EFFICACY OF A SURVIVIN THERAPEUTIC IN THE TREATMENT OF TUMORS [patent_app_type] => utility [patent_app_number] => 17/294713 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61400 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294713 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/294713
METHODS FOR IMPROVING THE EFFICACY OF A SURVIVIN THERAPEUTIC IN THE TREATMENT OF TUMORS Nov 17, 2019 Abandoned
Array ( [id] => 17830131 [patent_doc_number] => 20220267435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => COVALENT ADAPTOR SYNNOTCH AND CHIMERIC ANTIGEN RECEPTORS (CARS) FOR PROGRAMMABLE ANTIGEN-TARGETING [patent_app_type] => utility [patent_app_number] => 17/282113 [patent_app_country] => US [patent_app_date] => 2019-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24361 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282113 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/282113
Covalent adaptor synNotch and chimeric antigen receptors (CARs) for programmable antigen-targeting Oct 2, 2019 Issued
Menu